Danaher (DHR) has ceased trying to acquire Catalent (CTLT) after expressing interest in purchasing the contract manufacturer, Bloombreg’s Michelle F. Davis and Liana Baker report, citing people familiar with the matter. Danaher, which is no longer considering making an offer, had made overtures to Catalent valuing the company at a significant premium, the authors note. Catalent shares are down 6.5% after the news. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Catalent (NYSE:CTLT) Is Not on Danaher’s (NYSE:DHR) Buy List
- Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
- Danaher price target lowered to $270 from $290 at Barclays
- 5 Best Healthcare Stocks to Invest in Now, According to Analysts
- Citi puts ‘positive catalyst watches’ on three life science stocks